\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:02<\/td>\n | Welcome and Introduction<\/td>\n | Lanktree, Matthew (Canada)<\/td>\n<\/tr>\n | \n| 11:02 – 11:10<\/td>\n | Insights into ADPKD from genetic studies<\/td>\n | Lanktree, Matthew (Canada)<\/td>\n<\/tr>\n | \n| 11:10 – 11:35<\/td>\n | Clinical practice update and case presentations in ADPKD<\/td>\n | Pei, York (Canada)<\/td>\n<\/tr>\n | \n| 11:35 – 11:50<\/td>\n | Novel disease mechanisms in ADPKD<\/td>\n | Maski, Manish (United States)<\/td>\n<\/tr>\n | \n| 11:50 – 12:00<\/td>\n | Q&A<\/td>\n | All Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2020\/10\/LOGO-CALLIDITAS-THERA-e1606757305263.jpg\") <\/p>\n \n- Why Target the Mucosal Immune System of the Gut to Treat IgA Nephropathy?<\/strong><\/li>\n
- Organizer: <\/strong>Calliditas Therapeutics
\n<\/strong><\/li>\n- Room: <\/strong>Room 2<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong><\/strong>Barratt, Jonathan (United Kingdom)<\/li>\n
- \n
OPEN ACCESS CODE: ZUYIMR01<\/strong><\/h5>\n<\/li>\n- Schedule: <\/strong>
\n\n\n\n| <\/td>\n | Title<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:05<\/td>\n | Welcome and introductions<\/td>\n | Barratt, Jonathan (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:05 – 11:20<\/td>\n | Targets for new drug development in IgAN<\/td>\n | Rovin, Brad (United States)<\/td>\n<\/tr>\n | \n| 11:20 – 11:35<\/td>\n | The rationale for targeting the mucosal immune system in IgAN<\/td>\n | Barratt, Jonathan (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:35 – 11:50<\/td>\n | Clinical experience of targeting the Peyer\u2019s patches in IgAN<\/td>\n | Lafayette, Richard (United States)<\/td>\n<\/tr>\n | \n| 11:50 – 12:00<\/td>\n | Q+A<\/td>\n | Barratt, Jonathan (United Kingdom)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/02\/Bayer-logo.png\") <\/p>\n \n- Nonsteroidal MRAs: A new chapter for the management of CKD in T2D<\/strong><\/li>\n
- Organizer: <\/strong>Bayer AG<\/li>\n
- Room: <\/strong>Room 3<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong><\/strong>Pecoits-Filho, Roberto (United States)<\/li>\n
- \n
OPEN ACCESS CODE: ZUYIMR00<\/strong><\/h5>\n<\/li>\n- Schedule: <\/strong>
\n\n\n\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:05<\/td>\n | Welcome and introductions<\/td>\n | Pecoits-Filho, Roberto (United States)<\/td>\n<\/tr>\n | \n| 11:05 – 11:25<\/td>\n | Inflammation and fibrosis as a driver of CKD progression: An opportunity for intervention?<\/td>\n | Cherney, David (Canada)<\/td>\n<\/tr>\n | \n| 11:25 – 11:45<\/td>\n | Impact of MR antagonism in CKD in T2D: Lessons from the FIDELIO-DKD trial<\/td>\n | Bakris, George (United States)<\/td>\n<\/tr>\n | \n| 11:45 – 11:55<\/td>\n | Q+A<\/td>\n | All Faculty<\/td>\n<\/tr>\n | \n| 11:55 – 12:00<\/td>\n | Summary + Close<\/td>\n | Pecoits-Filho, Roberto (United States)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2020\/11\/Travere-logo.png\") <\/p>\n \n- Proteinuria Treatment Targets in Glomerular Disease: Providing Insights into Clinical Outcomes<\/strong><\/li>\n
- Organizer: <\/strong>Travere Therapeutics<\/li>\n
- Room: <\/strong>Room 1<\/li>\n
- Time: <\/strong>11:00 \u2013 12:30 EDT<\/li>\n
- Chair: <\/strong>Barbour, Sean (Canada)<\/li>\n
- \n
OPEN ACCESS CODE: RUYIMR04\u00a0<\/strong><\/h5>\n<\/li>\n- Schedule: <\/strong>
\n\n\n\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:10<\/td>\n | Introduction and setting the scene<\/td>\n | Barbour, Sean (Canada)<\/td>\n<\/tr>\n | \n| 11:10 – 11:25<\/td>\n | Proteinuria targets in FSGS<\/td>\n | Mariani, Laura (United States)<\/td>\n<\/tr>\n | \n| 11:25 – 11:35<\/td>\n | Proteinuria targets in IgAN<\/td>\n | Barbour, Sean (Canada)<\/td>\n<\/tr>\n | \n| 11:35 – 11:45<\/td>\n | Proteinuria as surrogate endpoint for regulatory approval of novel therapeutics in glomerular disease<\/td>\n | Carroll, Kevin J. (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:45 – 12:00<\/td>\n | Close, Q+A and integrated polling<\/td>\n | All Faculty<\/td>\n<\/tr>\n | \n| 12:00 – 12:30<\/td>\n | \nBreakout Room\u00a0<\/strong><\/h5>\n<\/td>\n| <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Industry Symposia Program (Saturday, April 17, 2021)” tab_id=”industry-symposia-program-17″][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/02\/CMHC-Updated-Logo_18.02.2021.png\") <\/p>\n \n- The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies<\/strong><\/li>\n
- Provider: <\/strong>Cardiometabolic Health Congress\u00a0 \u00a0 \u00a0 Supported by an unrestricted educational grant from Bayer Healthcare Pharmaceuticals Inc<\/li>\n
- Room: <\/strong>Room 5<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong>Bakris, George L. (United States)<\/li>\n
- \n
OPEN ACCESS CODE: ERBEDX99<\/strong><\/h5>\n<\/li>\n- Schedule: <\/strong>
\n\n\n\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:15<\/td>\n | Introduction, Background and Future of DKD<\/td>\n | Bakris, George L. (United States)<\/td>\n<\/tr>\n | \n| 11:15 – 11:30<\/td>\n | New Perspectives in the Management of CKD in T2D: the Emerging Role of MRAs<\/td>\n | Agarwal, Rajiv (United States)<\/td>\n<\/tr>\n | \n| 11:15 – 11:30<\/td>\n | Effect of Finerenone on CKD Outcomes in T2D<\/td>\n | Bakris, George L. (United States)<\/td>\n<\/tr>\n | \n| 11:30 – 11:45<\/td>\n | Finerenone and Cardiovascular Outcomes<\/td>\n | Filippatos, Gerasimos (Greece)<\/td>\n<\/tr>\n | \n| 11:45 – 12:00<\/td>\n | Panel Discussion, Q+A and Closing<\/td>\n | All Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/03\/AstraZeneca_logo.jpg\") <\/p>\n \n- SGLT2 inhibitors: The next step to optimal care in CKD<\/strong><\/li>\n
- Supported by an unrestricted educational grant from AstraZeneca<\/li>\n
- Room: <\/strong>Room 1<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong>Tuttle, Katherine (United States)<\/li>\n
- \n
OPEN ACCESS CODE: RUYIMR99<\/strong><\/h5>\n<\/li>\n- <\/li>\n
- Schedule: <\/strong>
\n\n\n\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:05<\/td>\n | Welcome and Introduction<\/td>\n | Tuttle, Katherine (United States)<\/td>\n<\/tr>\n | \n| 11:05 – 11:20<\/td>\n | Impacting clinical practice \u2013 SGLT2 inhibitors in CKD<\/td>\n | Correa-Rotter, Ricardo (Mexico)<\/td>\n<\/tr>\n | \n| 11:20 – 11:35<\/td>\n | How SGLT2 inhibitors fit in the CKD management framework<\/td>\n | Cherney, David (Canada)<\/td>\n<\/tr>\n | \n| 11:35 – 11:50<\/td>\n | Initiating SGLT2 inhibitors \u2013 the cardiologist\u2019s experience<\/td>\n | Jhund, Pardeep (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:50 – 12:00<\/td>\n | Evidence in practice, Q+A and panel discussion<\/td>\n | All Faculty<\/td>\n<\/tr>\n | \n| 12:00 – 12:30<\/td>\n | \nBreakout Room\u00a0<\/strong><\/h5>\n<\/td>\n| <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/03\/Connect2cme-LARGE2.png\") <\/p>\n \n- Kidney itch: what\u2019s new and what to do<\/strong><\/li>\n
- Organizer: <\/strong>Connect2 CME\u00a0 \u00a0 \u00a0 \u00a0 Supported by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma<\/li>\n
- Room: <\/strong>Room 4<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong>Rayner, Hugh (United Kingdom)<\/li>\n
- \n
OPEN ACCESS CODE: RUYIMR01<\/strong><\/h5>\n<\/li>\n- Schedule: <\/strong>
\n\n\n\n| <\/td>\n | Title<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:05<\/td>\n | Welcome and Introduction<\/td>\n | Rayner, Hugh (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:05 – 11:10<\/td>\n | A patient’s experience<\/td>\n | <\/td>\n<\/tr>\n | \n| 11:10 – 11:20<\/td>\n | The burden and impact of kidney itch worldwide<\/td>\n | Sukul, Nidhi (United States)<\/td>\n<\/tr>\n | \n| 11:20 – 11:30<\/td>\n | Why do kidney patients itch?<\/td>\n | Rigatto, Claudio (Canada)<\/td>\n<\/tr>\n | \n| 11:30 – 11:40<\/td>\n | An evidence-based approach to managing kidney itch in your patients<\/td>\n | Rayner, Hugh (United Kingdom)<\/td>\n<\/tr>\n | \n| 11:40 – 12:00<\/td>\n | Quiz and patient video
\nInteractive Q+A
\nClosing remarks<\/td>\n | <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text]![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/03\/BI_Lilly_LockUp.jpg\") <\/p>\n \n- A discussion with KDIGO: Individual optimization of management of CKD patients with diabetes and CVD comorbidities<\/strong><\/li>\n
- Supported by an unrestricted educational grant from the Boehringer Ingelheim and Lilly Alliance<\/li>\n
- Room: <\/strong>Room 3<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chair: <\/strong>Wanner, Christoph (Germany)<\/li>\n
- \n
OPEN ACCESS CODE: AUYIMR01<\/strong><\/h5>\n<\/li>\n- <\/li>\n
- Schedule: <\/strong>
\n\n\n\n| <\/td>\n | Title<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| <\/td>\n | Welcome and Introductions<\/td>\n | Wanner, Christoph (Germany)<\/td>\n<\/tr>\n | \n| 11:00 – 11:15<\/td>\n | SGLT2 inhibitors and GLP-1 receptor agonists: Different classes, different modes of kidney protection<\/td>\n | Lambers Heerspink, Hiddo (The Netherlands)<\/td>\n<\/tr>\n | \n| 11:15 – 11:30<\/td>\n | Case 1: Kidney benefits associated with current pharmacotherapies in patients with CKD and diabetes<\/td>\n | Rossing, Peter (Denmark)<\/td>\n<\/tr>\n | \n| 11:30 – 11:45<\/td>\n | Case 2: Cardiovascular benefits associated with current pharmacotherapies in patients with CKD and diabetes<\/td>\n | Michos, Erin (United States)<\/td>\n<\/tr>\n | \n| 11:45 – 12:00<\/td>\n | Panel discussion<\/td>\n | All Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Industry Symposia Program (Sunday, April 18, 2021)” tab_id=”industry-symposia-program-18″][vc_column_text]<\/p>\n \n- Treating Anemia of CKD: Real-World Clinical Experience with HIF-PH Inhibitors<\/strong><\/li>\n
- Supported by an unrestricted educational grant from AstraZeneca<\/li>\n
- Room: <\/strong>Room 1<\/li>\n
- Time: <\/strong>11:00 \u2013 12:00 EDT<\/li>\n
- Chairs: <\/strong>Levin, Adeera (Canada) + Hao, Chuan-Ming (China)<\/li>\n
- \n
OPEN ACCESS CODE: <\/strong>ZUYIMR99<\/strong><\/h5>\n<\/li>\n<\/ul>\n\n- Schedule: <\/strong>
\n\n\n\nTime<\/strong><\/td>\nTitle<\/strong><\/td>\nSpeaker<\/strong><\/td>\n<\/tr>\n\n| 11:00 – 11:15<\/td>\n | Welcome and Introduction<\/td>\n | Levin, Adeera (Canada)
\nHao, Chuan-Ming (China)<\/td>\n<\/tr>\n | \n| 11:15 – 11:35<\/td>\n | HIF-PH inhibitors: Evidence from clinical trials<\/td>\n | Provenzano, Robert (United States)<\/td>\n<\/tr>\n | \n| 11:35 – 11:50<\/td>\n | My clinical experience with HIF-PH inhibitors<\/td>\n | Hao, Chuan-Ming (China)<\/td>\n<\/tr>\n | \n| 11:50 – 12:00<\/td>\n | Chairs\u2019 summary and Q+A<\/td>\n | <\/td>\n<\/tr>\n | \n| 12:00 – 12:30<\/td>\n | \nBreakout Room<\/strong><\/h5>\n<\/td>\n| <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/li>\n<\/ul>\n [\/vc_column_text][vc_column_text] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
![\"\"](\"https:\/\/www.theisn.org\/wcn\/wp-content\/uploads\/sites\/2\/2021\/02\/Sanofi-logo.png\"){kind=logo}
<\/p>\n